Zhu Xiao-Feng, Wang Ting-Chun, Zhang Rong-Hua
Department of Traditional Chinese Medicine, The First Affiliated Hospital, Jinan University, Guangzhou 510630.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012 Apr;32(4):525-9.
To observe the effects of Yigu Capsule (YGC) containing serum on the differentiation and the expressions of osteoprotegerin (OPG) and bone morphogenetic protein 2 (BMP-2) in osteoblasts after treatment by advanced glycation end products (AGEs), and to explore the mechanisms of YGC for treating osteoporosis (OP).
Forty 10-month-old female Sprague Dawley (SD) rats were randomly divided into four groups equally, i.e., the low dose YGC group, the moderate dose YGC group, the high dose YGC group, and the blank control group. The YGC containing serum and the control serum were prepared with the method of gastric perfusion. Primary osteoblasts of newborn SD rats was extracted and cultured, then they were passaged and divided into five groups, i. e., the vehicle control group, the model group, the low dose YGC group, the moderate dose YGC group, and the high dose YGC group. The model group was treated by AGEs (400 mg/L), the three YGC groups were treated by AGEs (400 mg/L) and YGC containing serum at different concentrations. Alkaline phosphatase (ALP) activity, type I collagen (ColI), bone gla protein (BGP), and mineralization of osteoblasts were tested using pNPP, ELISA, and Alizarin dyeing. The mRNA and protein levels of BMP-2 and OPG were respectively determined using RT-PCR and ELISA.
Primary osteoblasts from newborn SD rats could be used well in this experiment. Compared with the vehicle control group, the ALP, ColI, BGP, the mRNA and protein levels of BMP-2 and OPG of osteoblasts decreased in the model group, and the mineralized nodes were reduced, showing statistical difference (P<0.01). Compared with the model group, the ALP, ColI, BGP, the mRNA and protein levels of BMP-2 and OPG of osteoblasts increased in the three YGC groups, and the mineralized nodes increased in a dose-dependent manner, showing statistical difference (P<0.05, P<0.01).
YGC containing serum could promote the differentiation and mineralization of osteoblasts, and improve the expressions of OPG and BMP-2 after treatment by AGEs. These might be one of YGC's mechanisms for treating OP.
观察含药血清益骨胶囊(YGC)对晚期糖基化终末产物(AGEs)作用后成骨细胞分化及骨保护素(OPG)、骨形态发生蛋白2(BMP-2)表达的影响,探讨YGC治疗骨质疏松症(OP)的作用机制。
将40只10月龄雌性Sprague Dawley(SD)大鼠随机均分为四组,即YGC低剂量组、YGC中剂量组、YGC高剂量组和空白对照组。采用灌胃法制备含药血清及对照血清。提取并培养新生SD大鼠原代成骨细胞,传代后分为五组,即空白对照组、模型组、YGC低剂量组、YGC中剂量组和YGC高剂量组。模型组用AGEs(400 mg/L)处理,三个YGC组用AGEs(400 mg/L)及不同浓度含药血清处理。采用对硝基苯磷酸酯法(pNPP)、酶联免疫吸附测定法(ELISA)及茜素红染色检测成骨细胞碱性磷酸酶(ALP)活性、Ⅰ型胶原(ColI)、骨钙素(BGP)及矿化情况。采用逆转录聚合酶链反应(RT-PCR)及ELISA分别检测BMP-2和OPG的mRNA及蛋白水平。
新生SD大鼠原代成骨细胞可很好地用于本实验。与空白对照组比较,模型组成骨细胞ALP、ColI、BGP、BMP-2及OPG的mRNA和蛋白水平均降低,矿化结节减少,差异有统计学意义(P<0.01)。与模型组比较,三个YGC组的成骨细胞ALP、ColI、BGP、BMP-2及OPG的mRNA和蛋白水平均升高,矿化结节呈剂量依赖性增加,差异有统计学意义(P<0.05,P<0.01)。
含药血清YGC可促进AGEs作用后成骨细胞的分化及矿化,提高OPG和BMP-2的表达。这可能是YGC治疗OP的作用机制之一。